Zenas BioPharma, Inc.
ZBIO
$7.54
-$0.26-3.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.00M | 0.00 | 50.00M | 50.00M | 50.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00M | 0.00 | 50.00M | 50.00M | 50.00M |
| Cost of Revenue | 139.14M | 110.40M | 86.22M | 67.33M | 60.03M |
| Gross Profit | -134.14M | -110.40M | -36.22M | -17.33M | -10.03M |
| SG&A Expenses | 29.75M | 22.64M | 20.21M | 18.31M | 17.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.89M | 133.04M | 106.44M | 85.64M | 77.15M |
| Operating Income | -163.89M | -133.04M | -56.44M | -35.64M | -27.15M |
| Income Before Tax | -156.56M | -128.67M | -54.46M | -45.53M | -36.82M |
| Income Tax Expenses | 429.00K | 301.00K | 301.00K | 301.00K | 301.00K |
| Earnings from Continuing Operations | -156.99 | -128.97 | -54.76 | -45.83 | -37.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.99M | -128.97M | -54.76M | -45.83M | -37.12M |
| EBIT | -163.89M | -133.04M | -56.44M | -35.64M | -27.15M |
| EBITDA | -163.75M | -132.91M | -56.31M | -35.52M | -27.03M |
| EPS Basic | -48.39 | -63.08 | -55.65 | -29.57 | -24.31 |
| Normalized Basic EPS | -30.22 | -39.18 | -21.58 | -14.20 | -10.91 |
| EPS Diluted | -48.39 | -63.09 | -56.11 | -30.03 | -24.77 |
| Normalized Diluted EPS | -30.22 | -39.18 | -24.33 | -16.95 | -13.66 |
| Average Basic Shares Outstanding | 52.75M | 12.36M | 6.20M | 6.17M | 6.12M |
| Average Diluted Shares Outstanding | 52.75M | 12.36M | 6.56M | 6.53M | 6.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
